**Title:** Data extraction and statistical errors: a quantitative critique of Gumley, Braehler, & Macbeth, (2014)

To the Editor:

1. **Introduction**

Oxytocin is a neuropeptide that been used as an experimental therapeutic for various psychiatric disorders. In particular, randomized controlled trails have investigated the effect of intranasal oxytocin (IN-OT) on reducing symptoms in schizophrenia. As the extant literature has been mixed, meta-analyses have been published on this topic. One such meta-analysis was published in the British Journal of Clinical Psychology (Gumley, Braehler, & Macbeth, 2014). The authors concluded that IN-OT significantly improved overall symptoms, negative symptoms, and positive symptoms. We found several errors in this paper and, when corrected, resulted in non-significance for all outcomes which suggests that the conclusions of the paper are incorrect. The aims of this letter are threefold: (1) we will outline several errors; (2) we will perform a meta-analysis on the reported outcomes; and (3) we will conclude by stating the importance of issuing a correction.

1. **Data extraction errors**

Gumley, Braehler, & Macbeth (2014) coded the effect estimates such that a positive effect indicated a positive effect of IN-OT. Accordingly, all studies that reported a positive effect of IN-OT should have the same sign (±). However, in Table 2 of Gumley, Braehler, & Macbeth (2014) there are several coding mistakes. For total symptoms, for example, 3 out of 4 effects were misspecified. While Feifel et al. (2010) and Pedersen, Gibson, Rau, & Salimi (2011) reported a positive effect of IN-OT, they were coded as negative in the paper under question. In turn, while Lee et al. (2013) reported that the IN-OT group actually had higher symptoms scores than the placebo group, Gumley, Braehler, & Macbeth (2014) coded this effect as though IN-OT had a positive effect on reducing symptoms. From the primary studies, we extracted the relevant data and found that 9 out of the 13 outcomes used to compute the meta-analytic estimates for each symptom type were incorrectly coded. Table 1 of the present letter provides an example of the misspecified effects for positive symptoms.

1. **Statistical errors**

Gumley, Braehler, & Macbeth (2014) fitted both fixed and random effects models. In their Table 2, both fixed and random effects estimates and corresponding confidence intervals (*CI*) were reported. By definition, the *CI* of a random effects estimate must be larger or equal to the CI of the fixed effects estimate when both are based on the same data. This is because in random effects models another variance source (variance in the true scores across studies) is added, which increases uncertainty in the estimates and thus the *CI*s. However, Gumley, Braehler, & Macbeth (2014) consistently reported *smaller* *CI*s for the random effects estimates as compared to the fixed effects estimates. Due to heterogeneity between outcomes, their conclusions were based on the random effect estimates and where therefore incorrect.

1. **Meta-analysis**

To check whether the aforementioned errors changed the conclusions of the paper, we performed a meta-analysis based on the data reported in Table 2 in Gumley, Braehler, & Macbeth (2014). We attempted to replicate their procedures as closely as possible, including outcomes used, effect size calculation (standardized mean difference: SMD), and we report both fixed and random effect models.

1. **Replication attempt**

While Gumley, Braehler, & Macbeth (2014) reported significant effects for all outcomes excluding general psychopathology, the data in their Table 2 did not support this conclusion. Based on the random effects models, all meta-analytic estimates were non-significant (*CI*s included zero): negative symptoms (SMD = 0.45, [-0.49, 1.39]), positive symptoms (SMD = 0.33, [-0.53, 1.19]), general psychopathology (SMD = 0.25, [-0.34, 0.83]), total symptoms (SMD = 0.47, [-0.46, 1.41]).

1. **Discussion**

Although Gumley, Braehler, & Macbeth (2014) is not a new article and they urged caution when interpreting their findings, there are several reasons this letter deserves attention. First, while they reported IN-OT produced significant effects on all aspects of symptomology in schizophrenia, our analysis suggests that all effects were non-significant. Second, IN-OT research has become a very active field and ensuring accuracy in the publish literature is a mental health priority. For instance, recent publications cite Gumley, Braehler, & Macbeth (2014) in support of IN-OT reducing psychiatric symptoms (Hofmann, Fang, & Brager, 2015). Third, the evidence from animal studies supporting the role of oxytocin in psychiatric disorders is substantial, especially those comprised of social deficits (Lim, Bielsky, & Young, 2005). By ensuring null results are represented in the literature, researchers can work towards improving current methods of delivery or dedicate more resources into developing pharmaceutical drugs that target oxytocin receptors. Together, we hope this letter simultaneously results in a correction and moves the field towards effective treatments, which is especially important because of the difficulty in treating certain aspects (e.g., negative symptoms) in schizophrenia.

Donald R. Williams1\*

Paul-Christian Bürkner2

1 Animal Behavior Graduate Group,

University of California, Davis

Davis, USA

2 Institute of Psychology, University of Muenster

Muenster, Germany

\*Corresponding Author

drwwilliams@ucdavis.edu

**Supplementary materials**

Data and R code for analyses presented in this letter are publicly available at Donald R. Williams’ Open Science Framework account (https://osf.io/mzcbr/)

**References**

Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., & Warlan, H. (2010). Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. *Biological*. Retrieved from http://www.sciencedirect.com/science/article/pii/S0006322310004798

Feifel, D., MacDonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., … Hadley, A. (2010). Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. *Biological Psychiatry*, *68*(7), 678–680. http://doi.org/10.1016/j.biopsych.2010.04.039

Gumley, A., Braehler, C., & Macbeth, A. (2014a). A meta-analysis and theoretical critique of oxytocin and psychosis: Prospects for attachment and compassion in promoting recovery. *British Journal of Clinical Psychology*, *53*(1), 42–61. http://doi.org/10.1111/bjc.12041

Gumley, A., Braehler, C., & Macbeth, A. (2014b). A meta-analysis and theoretical critique of oxytocin and psychosis: Prospects for attachment and compassion in promoting recovery. *British Journal of Clinical Psychology*, *53*(1), 42–61. http://doi.org/10.1111/bjc.12041

Hofmann, S. G., Fang, A., & Brager, D. N. (2015). Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies. *Psychiatry Research*, *228*(3), 708–714. http://doi.org/10.1016/j.psychres.2015.05.039

Lee, M. R., Wehring, H. J., McMahon, R. P., Linthicum, J., Cascella, N., Liu, F., … Kelly, D. L. (2013). Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study. *Schizophrenia Research*, *145*(1), 110–115. http://doi.org/10.1016/j.schres.2013.01.001

Lim, M. M., Bielsky, I. F., & Young, L. J. (2005). Neuropeptides and the social brain: potential rodent models of autism. *International Journal of Developmental Neuroscience*, *23*(2), 235–243. http://doi.org/10.1016/j.ijdevneu.2004.05.006

Modabbernia, A., Rezaei, F., Salehi, B., Jafarinia, M., Ashrafi, M., Tabrizi, M., … Akhondzadeh, S. (2013). Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia. *CNS Drugs*, *27*(1), 57–65. http://doi.org/10.1007/s40263-012-0022-1

Pedersen, C. A., Gibson, C. M., Rau, S. W., & Salimi, K. (2011). Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. *Schizophrenia*. Retrieved from http://www.sciencedirect.com/science/article/pii/S0920996411004257

Williams, D. R., & Bürkner, P.-C. (2016). Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis. Manuscript submitted for publication.

**Table 1:** Comparison of primary studies’ effect sizes for positive symptoms

|  |  |  |  |
| --- | --- | --- | --- |
| Primary study | SMD coded by  Gumley et al. (2014) | SMD coded in  (Williams & Bürkner, 2016) | |
| Feifel et al. (2010) | -0.10 | 0.39 |
| Modabbernia et al. (2013) | 1.17 | 1.12 |
| Pedersen et al. (2011) | -0.14 | 0.47 |

*Note:* The effect sizes from Gumley, Braehler, & Macbeth (2014) were obtained from Table 2 of their paper. In this example, 2 of the 3 outcomes had negative signs when they should have been positive.

**Table 2:** Comparison of meta-analytic estimates for the data of Gumley et al. (2014)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Model type | Symptom type | Estimates computed by Gumley et al. (2014) | | Estimates obtained by reanalyzing the data of Gumley et al. (2014) | |
|  |  | **SMD** | ***CI*** | **SMD** | ***CI*** |
| Fixed | Negative | 0.50 | [0.07, 0.93] | 0.49 | [0.06, 0.92] |
|  | Positive | 0.39 | [-0.04, 0.82] | 0.38 | [-0.04, 0.81] |
|  | General | 0.27 | [-0.16, 0.70] | 0.27 | [-0.15, 0.70] |
|  | Overall | 0.70 | [0.35, 1.05] | 0.52 | [0.15, 0.90] |
| Random | Negative | 0.47 | [0.17, 0.76] | 0.45 | [-0.49, 1.39] |
|  | Positive | 0.35 | [0.04, 0.66] | 0.33 | [-0.53, 1.19] |
|  | General | 0.25 | [-0.07, 0.57] | 0.25 | [-0.34, 0.83] |
|  | Total | 0.52 | [0.34, 0.70] | 0.47 | [-0.46, 1.41] |

*Note:* 3 out of 4 estimates for the fixed effects are similar between the two analyses. For the random effects models, however, the point estimates are similar but all confidence intervals include zero in our results. Accordingly, while Gumley, Braehler, & Macbeth (2014) reported significant effects for three outcomes, we show all meta-analytic estimates are non-significant.